1 recruiting, 1 terminated. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow AZD5991: new trials by email Literature Review of AZD5991 trials Research Report on AZD5991
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. AZD5991, AZD5991 + Venetoclax - Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Terminated | AstraZeneca | 70 | 2017-08-02 | 2022-09-23 |
| Study of Biomarker-Based Treatment of Acute Myeloid Leukemia Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis - Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2 / Phase 3 | Recruiting | Beat AML, LLC | 3000 | 2016-11-01 | 2026-09-03 |
Leukemia, Myeloid, Acute (1) · Recurrence (1)
AstraZeneca (1) · Beat AML, LLC (1)
United States (2)
Alice Mims, MD (1)